Breast conservation and axillary management after primary systemic therapy in patients with early-stage breast cancer: the Lucerne toolbox
Language English Country Great Britain, England Media print
Document type Consensus Development Conference, Journal Article, Practice Guideline, Research Support, Non-U.S. Gov't, Review
PubMed
33387500
DOI
10.1016/s1470-2045(20)30580-5
PII: S1470-2045(20)30580-5
Knihovny.cz E-resources
- MeSH
- Chemotherapy, Adjuvant MeSH
- Delphi Technique MeSH
- Clinical Decision-Making MeSH
- Consensus MeSH
- Medical Oncology standards MeSH
- Humans MeSH
- Breast Neoplasms pathology therapy MeSH
- Neoadjuvant Therapy adverse effects standards MeSH
- Antineoplastic Agents administration & dosage adverse effects MeSH
- Mastectomy, Segmental adverse effects standards MeSH
- Neoplasm Staging MeSH
- Treatment Outcome MeSH
- Check Tag
- Humans MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Consensus Development Conference MeSH
- Research Support, Non-U.S. Gov't MeSH
- Review MeSH
- Practice Guideline MeSH
- Names of Substances
- Antineoplastic Agents MeSH
Primary systemic therapy is increasingly used in the treatment of patients with early-stage breast cancer, but few guidelines specifically address optimal locoregional therapies. Therefore, we established an international consortium to discuss clinical evidence and to provide expert advice on technical management of patients with early-stage breast cancer. The steering committee prepared six working packages to address all major clinical questions from diagnosis to surgery. During a consensus meeting that included members from European scientific oncology societies, clinical trial groups, and patient advocates, statements were discussed and voted on. A consensus was reached in 42% of statements, a majority in 38%, and no decision in 21%. Based on these findings, the panel developed clinical guidance recommendations and a toolbox to overcome many clinical and technical requirements associated with the diagnosis, response assessment, surgical planning, and surgery of patients with early-stage breast cancer. This guidance could convince clinicians and patients of the major clinical advancements purported by primary systemic therapy, the use of less extensive and more targeted surgery to improve the lives of patients with breast cancer.
Breast Center Eastern Switzerland St Gallen Switzerland
Breast Center University Hospital Basel Basel Switzerland
Breast Centre Aarau Cham Zug Hirslanden Klinik Aarau Switzerland
Breast Surgery San Raffaele University and Research Hospital Milan Italy
Breast Surgical Oncology Unit Clinica Universidad de Navarra Universidad de Navarra Madrid Spain
Breast Unit Champalimaud Clinical Center and Foundation Lisbon Portugal
Brust Zentrum Zurich Zurich Switzerland
Brustzentrum Bern Biel Bern Switzerland
Comprehensive Cancer Center Medical University of Vienna Vienna Austria
Department of Surgery Antoni van Leeuwenhoek Netherlands Cancer Institute Amsterdam Netherlands
Europa Donna The European Breast Cancer Coalition Milan Italy
Heidelberg University Hospital Heidelberg Germany
Institut Jules Bordet Brussels Belgium; l'Université Libre de Bruxelles Brussels Belgium
Institute of Pathology Philipps University Marburg and University Hospital Marburg Marburg Germany
Istituto Europeo di Oncologia IRCCS and University of Milano Milan Italy
References provided by Crossref.org
Breast cancer: evaluating the axilla before, during, and after therapy-new challenges
